2. Search Result
Search Result
Results for "

NCI-N87

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

2

Fluorescent Dyes

1

Peptides

2

Inhibitory Antibodies

1

Click Chemistry

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-141598
    Datopotamab deruxtecan (solution)
    2 Publications Verification

    DS-1062 (solution); Dato-DXd (solution)

    		 TROP2 Antibody-Drug Conjugates (ADCs) Topoisomerase Cancer
    Datopotamab deruxtecan (DS-1062) solution is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 Kd of 0.74 nmol/L. Datopotamab deruxtecan solution consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan solution binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan solution disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan solution can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer .
    Datopotamab deruxtecan (solution)
  • HY-147340
    TL033

    Tirumotecan

    		 Drug-Linker Conjugates for ADC Cancer
    TL033 is a drug-Linker conjugates for ADC. TL033 contains a linker and bioactive small molecule toxins. TL033 can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer .
    TL033
  • HY-107367A
    Epertinib hydrochloride

    S-22611 hydrochloride

    		 EGFR Cancer
    Epertinib (S-22611) hydrochloride is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER4 and HER2, with IC50s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib hydrochloride shows potent antitumor activity . Epertinib (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Epertinib hydrochloride
  • HY-P991526
    M701

    		CD3 Cancer
    M701 is a T-cell engager bispecific humanized antibody targeting epithelial cell adhesion molecule (EpCAM) and cluster of differentiation 3 (CD3). M701 binds to EpCAM on tumor cells and CD3 on T cells, thereby linking the two cell populations to achieve targeted cytotoxicity and T cell-mediated cytotoxicity. M701 is applicable to research related to advanced epithelial solid tumors .
    M701
  • HY-100555
    CH5138303

    		HSP Infection Cancer
    CH5138303 is a potent and orally active Hsp90 inhibitor. CH5138303 shows high binding affinity for N-terminal Hsp90α, with Kd of 0.52 nM. CH5138303 shows potent anti-proliferative activity against human cancer cell lines (HCT116 and NCI-N87), with IC50 values of 0.098 and 0.066 μM, respectively. CH5138303 shows high oral bioavailability in mice (F=44.0%). CH5138303 shows potent antitumor efficacy in a human NCI-N87 gastric cancer xenograft model .
    CH5138303
  • HY-168489
    OBI-992 drug-linker

    		Drug-Linker Conjugates for ADC Cancer
    OBI-992 drug-linker is a drug-linker conjugate composed of a TOP I inhibitor Exatecan (HY-13631) and a linker. OBI-992 drug-linker exhibits antitumor property in mouse models and can be used for synthesis of ADC OBI-992 .
    OBI-992 drug-linker
  • HY-177008
    PROTAC HER2 degrader-1

    		PROTACs EGFR Apoptosis Akt ERK Cancer
    PROTAC HER2 degrader-1 is a highly selective HER2 PROTAC degrader, with a DC50 of 69 nM and a Dmax of 96%. PROTAC HER2 degrader-1 inhibits HER2-positive cell proliferation and tumor growth through persistent HER2 degradation and potent inhibition of downstream pathways (AKT and ERK). PROTAC HER2 degrader-1 induces apoptosis in BT-474 cells. PROTAC HER2 degrader-1 can be used for research of HER2-positive cancers. (Pink: HER2 ligand: (HY-177009); Black: Linker; Blue: CRBN ligand: (HY-W023573) .
    PROTAC HER2 degrader-1
  • HY-172970
    HQY1428

    		CDK DNA/RNA Synthesis Apoptosis Cancer
    HQY1428 is an orally active CDK12 inhibitor. HQY1428 inhibits DNA replication, causes G2/M arrest in SKOV3 cells, induces DNA double-strand breaks and apoptosis. HQY1428 has anti-tumor activity in the SKOV3 xenograft mouse model. HQY1428 combined with the HER2 inhibitor Lapatinib (HY-50898) in the NCI-N87 xenograft mouse model produces a synergistic therapeutic effect .
    HQY1428
  • HY-143319
    SPH5030

    		EGFR Cancer
    SPH5030 is a selective and irreversible HER2 inhibitor. SPH5030 inhibits HER2 WT and EGFR WT with IC50s of 3.51 and 8.13 nM, respectively. SPH5030 shows excellent activities against HER2 mutants. SPH5030 can be used for the research of cancer .
    SPH5030
  • HY-P99969
    Inetetamab

    CMAB-302; Cipterbin

    		 EGFR Cancer
    Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities .
    Inetetamab
  • HY-P2317
    Cecropin P1, porcine

    		Bacterial Endogenous Metabolite Infection
    Cecropin P1, porcine is an antibacterial peptide that can be isolated from the upper part of the small intestine of the pig. Cecropin P1, porcine shows antibacterial activity against Gram-negative bacteria. Cecropin P1, porcine shows antiviral activity and inhibits PRRSV infection .
    Cecropin P1, porcine
  • HY-158005
    Anticancer agent 195

    		Apoptosis Cancer
    Anticancer agent 195 (Compound 10) is an inhibitor for ELF3-MED23 PPI with Ki of 0.68 μM. Anticancer agent 195 induces apoptosis and exhibits antitumor activity .
    Anticancer agent 195
  • HY-147193A
    Nampt-IN-10 trihydrochloride

    		NAMPT Cancer
    Nampt-IN-10 trihydrochloride (compound 4) is a Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-10 trihydrochloride shows cellular potency to A2780 and CORL23 cell lines with IC50 values of 5 and 19 nM, respectively. Nampt-IN-10 trihydrochloride can be used as a novel non-antimitotic payload for antibody-drug conjugate (ADC) .
    Nampt-IN-10 trihydrochloride
  • HY-172664
    Trabectedin derivative 2

    		Drug Derivative Cancer
    Trabectedin derivative 2 (compound PL-12) is a trabectedin derivative that can be used in research on ovarian cancer, gastric cancer, and breast cancer .
    Trabectedin derivative 2
  • HY-W1117786
    Nampt-IN-10

    		ADC Payload NAMPT Cancer
    Nampt-IN-10 (Compound 4) is an efficient inhibitor of nicotinamide phosphoribosyltransferase (NAMPT). Nampt-IN-10 exhibits nanomolar-level inhibitory activity against cell lines such as MDA-MB453, NCI-N87, and NCI-H526. Nampt-IN-10 can be used as an ADC payload, and the ADC constructed with it as the core demonstrates significant anti-tumor activity .
    Nampt-IN-10
  • HY-170027
    LW1564

    		HIF/HIF Prolyl-Hydroxylase AMPK Cancer
    LW1564 is an inhibitor for HIF-1α with an IC50 of 1.2 µM in HepG2. LW1564 inhibits mitochondrial respiration, reduces ATP production, stimulates HIF-1α degradation, and inhibits proliferation of various cancer cells with GI50 of 0.4-4.6 μM. LW1564 activates AMPK signaling pathway and inhibits lipid synthesis. LW1564 exhibits antitumor in HepG2 xenograft mouse model .
    LW1564
  • HY-157085
    BX-2819

    		HSP Cancer
    BX-2819 is a Hsp90 inhibitor with an IC50 value of 41 nM. BX-2819 inhibits the proliferation of cancer cells. BX-2819 can significantly inhibit the growth of NCI-N87 and HT-29 tumors in nude mice .
    BX-2819
  • HY-176538
    Antiproliferative agent-72

    		HSP Cancer
    Antiproliferative agent-72 (Compound 10) is a Hsp90 inhibitor with a Kd of 11 nM. Antiproliferative agent-72 has antiproliferative activity with IC50s of 1.5  μM and 1.1 μM for HCT116 and NCI-N87 cells, respectively. Antiproliferative agent-72 can be used for cancers research .
    Antiproliferative agent-72
  • HY-15990
    CH5164840

    		HSP Cancer
    CH5164840 (16) shows high binding affinity for N-terminal Hsp90a (Kd = 0.52 nM) and strong anti-proliferative activity against human cancer cell lines (HCT116 IC50 = 0.15 μM, NCI-N87 IC50 = 0.066 μM). CH5164840 (16) is orally active (t1/2 = 2.64 h) with potent antitumor efficacy .
    CH5164840
  • HY-107367
    Epertinib

    S-22611

    		 EGFR Cancer
    Epertinib (S-22611) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER4 and HER2, with IC50s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib shows potent antitumor activity . Epertinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Epertinib
  • HY-163453
    HER2-IN-19

    		EGFR Cancer
    HER2-IN-19 (Compound 10e) is a potent inhibitor of HER2 and EGFR with IC50 values of 0.87 respectively and 3.5 nM. HER2-IN-19 has potent inhibitory activity against tumor cells, IC50 NCI-N87 = 1.63 nM, IC50 BT474= 15.17 nM, IC50 BaF3-HER2YVMA = 1.49 nM .
    HER2-IN-19
  • HY-151207
    Anticancer agent 81

    		Apoptosis ADC Payload Cancer
    Anticancer agent 81 (Compound 37b3) is an anticancer agent and can induce tumor cell cycle arrest and apoptosis. Anticancer agent 81 can be used as a payload to conjugate with Trastuzumab (HY-P9907) to obtain the antibody–agent conjugate (ADC) T-PBA. T-PBA maintained its mode of target and internalization ability of Trastuzumab .
    Anticancer agent 81
  • HY-176237
    Nampt-IN-16

    		NAMPT Apoptosis Cancer
    Nampt-IN-16 (Compound 9a) is an orally active NAMPT inhibitor with an IC50 of 0.15 μM. Nampt-IN-16 can reduce intracellular NAD + and ATP levels. Nampt-IN-16 can inhibit the proliferation, migration, and invasion, induce cell cycle arrest and apoptosis, and alter cellular metabolism of gastric cancer cells. Nampt-IN-16 can be used in the research of tumors such as gastric cancer .
    Nampt-IN-16
  • HY-111007
    CH5015765

    		HSP Cancer
    CH5015765 is an orally available Hsp90 inhibitor bound to the N-terminal ATP binding site, with a dissociation constant of 3.4 nM, CH5015765 exerts antiproliferative activity against human cancer cell lines, with IC50 values of 0.46 μM for HCT116 colorectal cancer cells and 0.57 μM for NCI-N87 gastric cancer cells. CH5015765 can be used for the study of cancer .
    CH5015765
  • HY-177414
    BB-1701

    		Antibody-Drug Conjugates (ADCs) EGFR Inflammation/Immunology Cancer
    BB-1701 is an anti-HER2 antibody-drug conjugate (ADC). BB-1701 is composed of a humanized anti-HER2 antibody (Trastuzumab) (HY-P9907), a linker (Mal-PEG2-VCP), a microtubule inhibitor (Eribulin) (HY-13442), and the drug-linker conjugate for ADC is Mal-PEG2-VCP-Eribulin (HY-128870). BB-1701 has a potent cytotoxicity and bystander effects on tumors with heterogeneous target expression. BB-1701 significantly induces immunogenic cell death and the activation of the immune .
    BB-1701
  • HY-115499
    MPC-0767

    		HSP Cancer
    MPC-0767 is a potent, selective, and orally active hsp90 inhibitor. MPC-0767 is an L-alanine ester proagent of MPC-3100 with improved chemical stability .
    MPC-0767
  • HY-164346
    Amine-PEG8-Val-Cit-PAB-MMAE

    		Microtubule/Tubulin Drug-Linker Conjugates for ADC Cancer
    Amine-PEG8-Val-Cit-PAB-MMAE is a potent drug-linker conjugate for antibody-drug conjugates (ADCs).Amine-PEG8-Val-Cit-PAB-MMAE consists of the linker amine-PEG8-Vali-Cit-PAB and the payload MMAE (HY-15162), and can be used to synthesize ADCs. Amine-PEG8-Val-Cit-PAB-MMAE can be used for the research of gastric cancer, colon cancer, lung adenocarcinoma .
    Amine-PEG8-Val-Cit-PAB-MMAE
  • HY-107367AR
    Epertinib hydrochloride (Standard)

    S-22611 hydrochloride (Standard)

    		 Reference Standards EGFR Cancer
    Epertinib hydrochloride (Standard) (S-22611 hydrochloride (Standard)) is the analytical standard of Epertinib (hydrochloride) (HY-107367A). This product is intended for research and analytical applications. Epertinib (S-22611) hydrochloride is a potent, orally active, reversible, and selective tyrosine Kinase inhibitor of EGFR, HER4 and HER2, with IC50s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib hydrochloride shows potent antitumor activity . Epertinib (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Epertinib hydrochloride (Standard)
  • HY-181679
    TML-2Cl

    		ADC Linker Cancer
    TML-2Cl is a dichloro-modified trimethyl lock adapter for antibody-drug conjugates and payload releaser.TML-2Cl undergoes 1,6-elimination followed by rapid self-cyclization to facilitate release of the payload Exatecan after cathepsin B cleavage of the associated linker.TML-2Cl exhibits high stability when conjugated to a drug and high intrinsic hydrophobicity.TML-2Cl can be used for the research of gastric carcinoma .
    TML-2Cl
  • HY-183594
    Exatecan-(D-2,4-DHB)-NH2-AA(bPEG8)-Mal

    		Drug-Linker Conjugates for ADC Others
    Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal is a linker-payload conjugate. Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal contains the linker D-2,4-DHB-NH2-AA(bPEG8)-Mal (HY-183595) and the cytotoxic agent Exatecan (HY-13631), a potent DNA topoisomerase I inhibitor. Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal can be utilized for the development of antibody-drug conjugates (ADCs) .
    Exatecan-(D-2,4-DHB)-NH2-AA(bPEG8)-Mal

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: